 |
PDBsum entry 2xm9
|
|
|
|
|
 |
Contents |
 |
|
|
|
|
|
|
|
|
|
|
|
|
* Residue conservation analysis
|
|
|
|
|
|
PDB id:
|
|
|
|
| Name: |
|
Transferase
|
|
|
Title:
|
|
Structure of a small molecule inhibitor with the kinase domain of chk2
|
|
Structure:
|
|
Serine/threonine-protein kinase chk2. Chain: a. Fragment: kinase domain, residues 210-531. Synonym: cds1, checkpoint kinase 2. Engineered: yes
|
|
Source:
|
|
Homo sapiens. Human. Organism_taxid: 9606. Expressed in: escherichia coli. Expression_system_taxid: 562.
|
|
Resolution:
|
|
|
2.50Å
|
R-factor:
|
0.189
|
R-free:
|
0.238
|
|
|
Authors:
|
|
J.J.Caldwell,E.J.Welsh,C.Matijssen,V.E.Anderson,L.Antoni,K.Boxall, F.Urban,A.Hayes,F.I.Raynaud,L.J.Rigoreau,T.Raynham,G.W.Aherne, L.H.Pearl,A.W.Oliver,M.D.Garrett,I.Collins
|
|
Key ref:
|
|
J.J.Caldwell
et al.
(2011).
Structure-based design of potent and selective 2-(quinazolin-2-yl)phenol inhibitors of checkpoint kinase 2.
J Med Chem,
54,
580-590.
PubMed id:
|
|
|
Date:
|
|
|
26-Jul-10
|
Release date:
|
12-Jan-11
|
|
|
|
|
|
|
PROCHECK
|
|
|
|
|
|
Headers
|
|
|
|
References
|
|
|
|
|
|
|
|
O96017
(CHK2_HUMAN) -
Serine/threonine-protein kinase Chk2 from Homo sapiens
|
|
|
|
Seq:
Struc:
|
|
|
|
543 a.a.
287 a.a.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Key: |
 |
PfamA domain |
|
|
 |
Secondary structure |
|
 |
CATH domain |
|
|
|
|
|
|
|
|
|
|
|
|
|
Enzyme class:
|
|
E.C.2.7.11.1
- non-specific serine/threonine protein kinase.
|
|
|
|
|
|
|
Reaction:
|
|
|
1.
|
L-seryl-[protein] + ATP = O-phospho-L-seryl-[protein] + ADP + H+
|
|
2.
|
L-threonyl-[protein] + ATP = O-phospho-L-threonyl-[protein] + ADP + H+
|
|
|
|
|
|
|
L-seryl-[protein]
|
+
|
ATP
|
=
|
O-phospho-L-seryl-[protein]
|
+
|
ADP
|
+
|
H(+)
|
|
|
|
|
|
|
L-threonyl-[protein]
|
+
|
ATP
|
=
|
O-phospho-L-threonyl-[protein]
|
+
|
ADP
|
+
|
H(+)
|
|
|
|
|
|
|
|
|
|
|
|
|
Molecule diagrams generated from .mol files obtained from the
KEGG ftp site
|
|
|
|
|
|
|
|
|
|
|
|
|
|
 |
|
|
|
|
|
|
| |
|
|
| |
|
|
J Med Chem
54:580-590
(2011)
|
|
PubMed id:
|
|
|
|
|
|
| |
|
Structure-based design of potent and selective 2-(quinazolin-2-yl)phenol inhibitors of checkpoint kinase 2.
|
|
J.J.Caldwell,
E.J.Welsh,
C.Matijssen,
V.E.Anderson,
L.Antoni,
K.Boxall,
F.Urban,
A.Hayes,
F.I.Raynaud,
L.J.Rigoreau,
T.Raynham,
G.W.Aherne,
L.H.Pearl,
A.W.Oliver,
M.D.Garrett,
I.Collins.
|
|
|
|
|
| |
ABSTRACT
|
|
|
|
| |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
 |
 |
 |
|
Literature references that cite this PDB file's key reference
|
|
|
| |
PubMed id
|
|
Reference
|
|
|
|
|
|
M.D.Garrett,
and
I.Collins
(2011).
Anticancer therapy with checkpoint inhibitors: what, where and when?
|
| |
Trends Pharmacol Sci,
32,
308-316.
|
|
|
|
|
|
The most recent references are shown first.
Citation data come partly from CiteXplore and partly
from an automated harvesting procedure. Note that this is likely to be
only a partial list as not all journals are covered by
either method. However, we are continually building up the citation data
so more and more references will be included with time.
|
|
Links
